©The Author(s) 2025.
World J Gastroenterol. Sep 21, 2025; 31(35): 110152
Published online Sep 21, 2025. doi: 10.3748/wjg.v31.i35.110152
Published online Sep 21, 2025. doi: 10.3748/wjg.v31.i35.110152
Figure 2 Kaplan-Meier curves.
A: For overall survival in patients with colorectal cancer lung metastases undergoing radiofrequency ablation (median, 37.8 months); B: For progression-free survival in patients with colorectal cancer lung metastases undergoing radiofrequency ablation (median, 18.7 months); C: For local tumor progression in patients with colorectal cancer lung metastases undergoing radiofrequency ablation (median, 35.6 months).
- Citation: Li KN, Ying LL, Du N, Wang Y, Huang HZ, Wang YH, Xu LC, Zhao Q, Song G, Hu YB, Li WT, Yan Y, Chen C, He XH. Radiofrequency ablation with or without capecitabine maintenance therapy for lung oligometastases from colorectal cancer. World J Gastroenterol 2025; 31(35): 110152
- URL: https://www.wjgnet.com/1007-9327/full/v31/i35/110152.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i35.110152